# 1 Title page

2 3	Title:	Representation of evidence-based clinical practice guideline recommendations on FHIR
4 5	Authors:	Gregor Lichtner <sup>1,2,3</sup> , Carlo Jurth <sup>3</sup> , Brian S Alper <sup>4,5</sup> , Claudia Spies <sup>3,6</sup> , Martin Boeker <sup>7</sup> , Joerg J Meerpohl <sup>8,9</sup> , Falk von Dincklage <sup>1,2,3</sup>
6 7		<sup>1</sup> Universitätsmedizin Greifswald, Department of Anesthesia, Critical Care, Emergency and Pain Medicine, Greifswald, Germany.
8 9 10		<sup>2</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Medical Informatics, Berlin, Germany.
11 12 13		<sup>3</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Anesthesiology and Operative Intensive Care Medicine, Berlin, Germany.
14		<sup>4</sup> Computable Publishing LLC, Ipswich, Massachusetts USA.
15		<sup>5</sup> Scientific Knowledge Accelerator Foundation, Ipswich, Massachusetts USA.
16 17 18 19		<ul> <li><sup>6</sup> Einstein Center Digital Future, Berlin, Germany.</li> <li><sup>7</sup> Institute for Artificial Intelligence and Informatics in Medicine, Chair of Medical Informatics, Medical Center rechts der Isar, Technical University of Munich, Munich, Germany.</li> </ul>
20 21		<sup>8</sup> Institute for Evidence in Medicine, Medical Center & Faculty of Medicine, University of Freiburg, Freiburg, Germany.
22 23		<sup>9</sup> Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.

## 24 Abstract

#### 25 Background

Various formalisms have been developed to represent clinical practice guideline recommendations in a computer-interpretable way. However, none of the existing formalisms leverage the structured and computable information that emerge from the evidence-based guideline development process. Thus, we here propose a FHIR-based guideline representation format that is structurally aligned to the knowledge artifacts emerging during the process of evidence-based guideline development.

#### 31 Methods

We identified the information required to represent evidence-based clinical practice guideline recommendations and reviewed the knowledge artifacts emerging during the evidence-based guideline development process. Then we conducted a consensus-based design process with domain experts to develop an information model for guideline recommendation representation that is structurally aligned to the evidence-based guideline recommendation development process and a corresponding representation based on evidence-based medicine (EBM)-on-FHIR resources.

#### 38 Results

39 The information model of clinical practice guideline recommendations and its EBMonFHIR-based 40 representation contain the clinical contents of individual guideline recommendations, a set of 41 metadata for the recommendations, the ratings for the recommendations (e.g., strength of 42 recommendation, certainty of overall evidence), the ratings of certainty of evidence for individual 43 outcomes (e.g., risk of bias) and links to the underlying evidence (systematic reviews based on primary 44 studies). We created profiles and an implementation guide for all FHIR resources required to represent 45 a complete clinical practice guideline and used the profiles to implement an exemplary clinical 46 guideline recommendation.

#### 47 Conclusions

48 Our EBMonFHIR-based representation of clinical practice guideline recommendations allows to 49 directly link the evidence assessment process through systematic reviews and evidence grading, and 50 the underlying evidence from primary studies to the resulting guideline recommendations. This not 51 only allows to evaluate the evidence on which recommendations are based on transparently and 52 critically, but also allows for a more direct and in future automatable way to generate computer-53 interpretable guideline recommendations based on computable evidence.

### 54 Introduction

55 A plethora of approaches have been developed to specify computer-interpretable representations of 56 clinical practice guideline recommendations, such as Asbru, EON, GLIF3, SAGE or GUIDE [1–7]. Despite 57 their many differences, all these representations have in common that they are designed based on the 58 concept that computer-interpretable guideline recommendations are derived by translating 59 unstructured recommendations into the formalism of the respective representation. However, with the emergence of evidence-based medicine over the last decades [8], guideline recommendations are 60 61 developed in a structured process in which knowledge artifacts, such as the effect size estimates from 62 primary studies or the grading of available evidence, are derived at each step. Leveraging these 63 structured knowledge artifacts for the computer-interpretable representation of clinical guideline 64 recommendations might require a reconsideration of the current computer-interpretable guideline 65 recommendation formalisms.

66 The systematic development process of evidence-based guideline recommendations for a specific 67 clinical question is based on a systematic review of studies providing data that address the clinical question, potentially followed by aggregations of the study data in meta-analyses and finally balancing 68 and grading all available information in structured evidence-to-decision frameworks, resulting in 69 70 trustworthy recommendations [9–12]. With digitalization spreading, more and more structured data 71 becomes available from this process. Considering that this structured data is the basis to formulate 72 unstructured guideline recommendations, translating these unstructured guideline recommendations 73 back into structured recommendation representations induces unnecessary workload. As an 74 alternative approach, we propose a format to represent computer-interpretable guideline 75 recommendations in a structure that directly builds on the knowledge artifacts emerging during the 76 guideline recommendation development process.

77 To represent such knowledge artifacts that emerge during guideline recommendation development, 78 the HL7 Clinical Decision Support (CDS) Work Group-sponsored Evidence-based Medicine (EBM) on 79 Fast Healthcare Interoperable Resources (FHIR) project sub-work group (EBMonFHIR) created a 80 collection of FHIR resources [13]. These FHIR resources provide a standardized way of describing data formats and elements that are related to both the evidence generation and evidence assessment parts 81 82 of evidence-based guideline development, such as the effect size for certain outcomes of a specific 83 intervention on a specific population, the grading of the certainty of evidence, and metadata such as 84 the group of authors or publication status and version of knowledge artifacts.

Based on these resources, we developed an interoperable, computer-interpretable representation of
 clinical practice guideline recommendations that combines the structured data emerging during the
 development of evidence-based guideline recommendations, from the evidence generation in primary

- 88 studies and systematic reviews and the structured evidence assessment in evidence-to-decision
- 89 frameworks to the resulting guideline recommendations.

## 90 Methods

#### 91 Requirements Engineering

92 To establish which information about the contents and the metadata of clinical practice guideline 93 recommendations need to be captured in the FHIR-based representation, we performed an iterative 94 consensus-based requirements engineering process. In this process, we included five clinical 95 stakeholders (health care professionals) and five guideline developers from German university 96 hospitals, medical societies and Cochrane Germany to identify both the required information for 97 practical use of clinical guideline recommendations and the metadata that is required to assess e.g. 98 the credibility and strength of recommendations, as well as the information required to connect 99 individual recommendations to their underlying evidence from systematic reviews of primary studies. 100 Participants of the requirements engineering process were recruited from the members of the COVID-101 19 evidence ecosystem (CEOsys) project of the German COVID-19 Research Network of University 102 Medicine ("Netzwerk Universitätsmedizin") [14].

#### 103 Information Modelling

After establishing the list of required information, we developed an information model of the collected items by identification of the item types, item cardinalities, relationships between items and grouping of the items. Input from clinical stakeholders and guideline developers helped defining the entity relationships for the items. The Cochrane PICO Ontology guided discussions for medical relationships among the recommendation contents [15]. The candidate models were reviewed with clinical stakeholders and medical information scientists for semantic and syntactic appropriateness and completeness.

#### 111 FHIR Mapping

Following the definition of the information model, we performed an iterative consensus-based process to map the model's items and relationships to their correspondences in FHIR. We included FHIR developers and EBMonFHIR maintainers as well as the clinical stakeholders and guideline developers from the requirements engineering process for necessary feedback and validation of the mapping.

In close collaboration with the EBMonFHIR maintainers, we derived a mapping of the information model to existing EBMonFHIR resources. During this process, suboptimal applicability of the resources to our use case were resolved by introducing differential changes to the EBMonFHIR resources in the FHIR specification. We therefore developed our FHIR profiles and implementation guide based on the latest available FHIR development build, which was at the time of writing the daily continuous integration build of FHIR R5 as of April 1, 2022.

#### 122 Development

123 The specification of the appropriate use of FHIR resources for representation of clinical guideline 124 recommendations was performed by means of creating FHIR resource profiles and an implementation 125 guide. Development was performed using software versioning and continuous integration and 126 continuous development (CI/CD) workflows on GitHub [16].

To maximize ease of implementation and adherence to the FHIR standard, the development of FHIR
 profiles was carried out under the condition that no extensions should be used in the profiles unless
 necessary.

- Profiling was performed using the FHIR ShortHand (FSH) language (version 1.2.0) and the SUSHI software (version 2.3.0) for translation to FHIR structure definitions in JSON format. For each profile, we required that at least one instance (i.e., example) was defined that instantiated that profile. Automated syntax and code checking were performed using the HL7 FHIR validator as implemented in
- the FSH validator python package (version 0.2.2; [17]). This package was also used to test and validate
- each defined instance against the profile it instantiates in the CI/CD workflow.
- The implementation guide was created using the HL7 FHIR IG Publisher tool version 1.1.115-SNAPSHOT (modified) and the FHIR core artifacts version 5.6.41-SNAPSHOT (modified). Both software tools were modified to implement the continuous integration FHIR build as of April 1, 2022. Modified sources and compiled executables are provided in the respective repositories of our GitHub organization [18].
- A custom template was used for creation of the implementation guide's html pages. The creation and deployment of the implementation guide to GitHub pages [19] is automatically triggered by commits to the main branch of the project's GitHub repository in order to always keep the source profiles and the implementation guide in synchronization.


#### 144 Evaluation

To evaluate syntactic and semantic completeness and appropriateness of the EBMonFHIR-based guideline recommendation representation, we implemented a recent COVID-19 guideline recommendation for the treatment of hospitalized patients. The implementation was reviewed with clinical stakeholders and medical information scientists to confirm the appropriateness and completeness of the implemented information.

## 151 Results

#### 152 Information model

We identified the required and optional information that need to be captured in a representation of 153 154 clinical guideline recommendations and categorized these information items into groups on two 155 dimensions (Figure 1). The first dimension describes the content type categories of the information 156 items including (i) items describing the medical relationships, (ii) the metadata items such as study 157 types or authors, and (iii) items describing the justification for the recommendation, including statistics 158 of primary studies and systematic reviews as well as the gradings of individual outcomes and of the final guideline recommendation. The second dimension describes the stages of the guideline 159 recommendation development process from (i) the primary evidence generation in clinical studies, (ii) 160 the systematic review and evidence assessment of individual outcomes, and (iii) the derivation of the 161 162 recommendation including evidence grading across all outcomes. In the following sections, we provide 163 details on each of the content type categories.



164

165 Figure 1 High level information model of the guideline recommendation representation.

#### 166 Medical relationships

167 The medical relationships that a clinical question is made of can be decomposed using the "PICO" 168 framework into the four components of Population, Intervention, Comparison and Outcome. These 169 components distinctly define to which patients a clinical question applies (population), which 170 intervention or treatment is considered (intervention), which control treatment is used as a 171 comparison for the investigated intervention (comparison) and which outcome is considered (outcome). Using the PICO framework to decompose the clinical questions of primary clinical studies 172 173 and meta-analyses is standard methodology in evidence-based medicine [20]. To leverage the PICO 174 framework to describe the medical relationships of guideline recommendations, only the two 175 components P and I are required. These allow to define distinctly in which patients (the "population") 176 which treatment or action (the "intervention") is recommended. As guideline recommendations are 177 commonly defined as absolute recommendations and not in relation to a specific comparison, the 178 comparison component of PICO is not required to describe the medical relationship of a guideline 179 recommendation. Likewise, as guideline recommendations summarize across all outcomes, the 180 individual outcomes are not a required component of the recommendation itself. Instead, a guideline 181 recommendation could include an "outcome net effect" (see "justification" below), but this does not 182 require describing a specific outcome on the guideline recommendation level.

#### 183 Metadata

The metadata category considers descriptive metadata such as the authors of all parts of the guideline development process including those of the clinical studies, the systematic review, the evidence assessment, and of the grading of the final recommendation. The metadata may also include versioning information of the recommendation (e.g., version number, date, publication status), which are particularly important in the context of living guidelines that are regularly updated. Additionally, citations of individual studies, published systematic reviews, recommendations and guidelines are part of the metadata.

#### 191 Justification

The justification category considers all information items on the basis of which the recommendation is ultimately given. For individual outcomes, these include the effect size (i.e., outcome statistics) of the intervention as determined from clinical studies or the systematic review and furthermore the quality of evidence rating according to GRADE [12]. For the final recommendation as a whole, the justification includes ratings according to the GRADE Evidence-to-Decision (EtD) [9,10] as well as the outcome net effect of the recommended intervention (weighting of benefits and harms) [21].

#### 198 FHIR Mapping

199 Overview


The structure of our EBMonFHIR-based guideline representation combines multiple interlinked FHIR resources for the representation of the different parts and aspects of a clinical practice guideline and the individual recommendations (Table 1). The definition of the recommended intervention serves as the root of the structure and references the group of patients ("population") for which the intervention is recommended, as well as the recommendation ratings according to the GRADE EtD framework (Figure 2). We created profiles for each resource to consistently constrain the representation of the clinical guideline recommendations. The following sections describe each of the profiles in more detail.

Category	Item	FHIR Resource(s)	Profile Name(s)	Required
Guideline	Collection of recommendations	Composition	Guideline	
Recommendation	Population	EvidenceVariable	RecommendationEligibilityCriteria	✓
	Intervention	PlanDefinition,	RecommendationPlan,	✓
		ActivityDefinition	RecommendationAction	
	Recommendation Citation	Citation	RecommendationCitation	
	Guideline Citation	Citation	GuidelineCitation	
Recommendation	Strength of Recommendation	ArtifactAssessment	RecommendationJustification	
Justification	Consensus	-		
	Benefits and Harms	- - - -	-	
	Certainty of Evidence			
	Preference and values			
	Resources			
	Equity			
	Acceptability	-		
	Feasibility	-		
Outcome	Outcome Definition	EvidenceVariable	OutcomeDefinition	
	Certainty of Evidence	ArtifactAssessment	CertaintyOfEvidenceRating	
	Clinical Importance			
	Risk of Bias	-		
	Inconsistency	-		
	Indirectness	-	-	
	Imprecision	-		
	Publication Bias	-		
	Large Effect	-		
	Plausible Confounders	-		
	Dose-Response Gradient	-		
Net Effect	Net Effect	Evidence	NetEffectEstimate	
Studies (primary	Intended Study Population	EvidenceVariable	StudyEligibilityCriteria	
& systematic	Intervention/Comparison	EvidenceVariable	InterventionDefinition	
reviews)	Study Citation	Citation	StudyCitation	
Primary Studies	Observed Study Population	Group	StudyCohort	
	Outcome Statistics (relative effect / mean difference)	Evidence	StudyOutcomeEvidence	
Systematic	Observed Populations from Primary Studies	Group	EvidenceSynthesisCohorts	
reviews	Aggregated Outcome Statistics	Evidence	OutcomeEvidenceSynthesis	
	Observed Outcomes from Primary Studies	EvidenceVariable	EvidenceDataSet	

207 Table 1 Information items of evidence-based clinical practice guidelines and their mapping to FHIR.

209 respective item.

<sup>208</sup> Shown are the items and the FHIR resource name and profile name, which are used to represent the



211

Figure 2 Overview of the resources and profiles used for representing clinical practice guideline recommendations on EBMonFHIR. Note that depending on the type of study (primary study vs systematic review), the PICO elements (eligibility criteria, intervention definition, outcome definition) for the evidence may be part of evidence generation or evidence assessment, respectively.

#### 216 Intervention

The recommended intervention is represented in the *RecommendationPlan* profile of the *PlanDefinition* resource. This resource allows to specify detailed clinical workflows, consisting of individual actions that are to be taken (or should not be taken) during specified circumstances. These individual actions are defined using the *RecommendationAction* profile of the *ActivityDefinition* resource and are referenced by the *RecommendationPlan* profile.

222 The RecommendationPlan profile serves as the root of an individual guideline recommendation representation, referencing – directly or indirectly – all further defining parts of an individual guideline 223 recommendation. Most importantly, the profile directly references the definition of the population, 224 225 for which the specified intervention is recommended, via the subjectReference field. The RecommendationPlan profile, together with the RecommendationAction profile and the 226 227 RecommendationEligibilityCriteria profiles form the required core of a computer-interpretable guideline recommendation representation that allows for automated integration with clinical data to 228 229 provide clinical decision support.

Next to the core components, the *RecommendationPlan* profile references via the *relatedArtifact* field
 the *RecommendationJustification* profile of the *ArtifactAssessment* resource to represent the

justification of the recommendation in accordance with the GRADE EtD framework. Additionally, the *RecommendationPlan* profile references the *RecommendationCitation* and *GuidelineCitation* profiles of the *Citation* resource to provide references to the published recommendation and/or guideline that contains the recommendation, respectively.

The InterventionDefinition profile of EvidenceVariable is used to represent the general, non-executable definition of an intervention in clinical studies or systematic reviews. In contrast to *RecommendationPlan* and *RecommendationAction*, the intervention represented by the InterventionDefinition profile does not usually describe the intervention in sufficient detail to provide automated clinical decision support.

#### 241 Population

242 The patients to which the recommended intervention defined in the *RecommendationPlan* profile is applicable is specified via the RecommendationEligibilityCriteria profile of the EvidenceVariable 243 244 resource. This profile leverages the newly introduced option of the EvidenceVariable resource to 245 specify complex characteristics for a population definition, such as temporal dependencies between 246 individual characteristics. Thereby, the EvidenceVariable resource allows to specify much more 247 complex population characteristics than the Group resource, and such complex definitions are 248 required to represent population definitions from actual guideline recommendations as well as from 249 study eligibility criteria.

#### 250 Recommendation Justification

251 To represent the rating of the recommendation regarding its strength, the achieved consensus among 252 the guideline developers, the certainty of evidence and additional ratings according to the GRADE EtD 253 framework [10], the RecommendationJustification profile of the ArtifactAssessment resource is used. 254 The ArtifactAssessment resource is newly introduced in FHIR Release 5 and is used to represent one or 255 more comments, ratings, or classifications about another resource. Here, that other resource is the 256 *RecommendationPlan* profile that describes the guideline recommendation. The profile includes the 257 individual ratings as justification for the recommendation in the content field and uses different value 258 sets and code systems for the individual components (Table 2).

Additionally, *RecommendationJustification* references the ratings of individual evidence (i.e., primary studies or meta-analyses) in accordance with GRADE via the *CertaintyOfEvidenceRating* profile of *ArtifactAssessment*. The *RecommendationJustification* profile also references the *NetEffectEstimate* profile of the Evidence resource to describe the combined net effect (net harm / net benefit) of the recommendation given the considered outcomes [21].

A single instance of the *RecommendationJustification* profile is used for a particular recommendation.

### 265 Certainty of Evidence Rating

The ratings of the individual outcomes that are relevant to a specific recommendation are represented using the *CertaintyOfEvidenceRating* profile of the *ArtifactAssessment* resource (Table 3). The assessed artifact for each *CertaintyOfEvidenceRating* instance is an instance of the *StudyOutcomeEvidence* or *OutcomeEvidenceSynthesis* profile of the *Evidence* resource, which represents the statistics related to that specific outcome and references the systematically collated body of evidence from which the effect estimates are derived. For each individual outcome, a different instance of the *CertaintyOfEvidenceRating* profile is used.

Item	ValueSet	CodeSystem	Defined	Codes
			by	
Strength of	RecommendationStrength	RecommendationStrength	CEOsys	strong-for   strong-against   weak-for   weak-against
Recommendation				
Consensus	RatingConsensus	StrengthOfRecommendationRating	FHIR	strong  weak
Benefits and Harms	RatingCertaintyOfEvidence	EvidenceCertaintyRating	FHIR	high  moderate   low   very-low
Certainty of Evidence	RatingBenefitAndHarms	EvidenceToDecisionCertaintyRating	CEOsys	small-net-benefit   substantial-net-benefit   important-harms
Preference and values	RatingPreferenceAndValues	EvidenceToDecisionCertaintyRating	CEOsys	factor-not-considered  substantial-variability  no-substantial-variability   few-want-intervention
Resources	RatingResources	EvidenceToDecisionCertaintyRating	CEOsys	factor-not-considered   important-issues-or-not-investigated   no-important-issues   important-negative-issues
Equity	RatingEquity	EvidenceToDecisionCertaintyRating	CEOsys	factor-not-considered   important-issues-or-not-investigated   no-important-issues   intervention-increases-inequity
Acceptability	RatingAcceptability	EvidenceToDecisionCertaintyRating	CEOsys	factor-not-considered   important-issues-or-not-investigated   no-important-issues   intervention-poorly-accepted
Feasibility	RatingFeasibility	EvidenceToDecisionCertaintyRating	CEOsys	factor-not-considered  important-issues-or-not-investigated   no-important-issues   intervention-difficult-to- implement

274 Table 2 Ratings in the RecommendationJustification profile. Shown are the ratings that are represented in the RecommendationJustification profile, together with the value set

275 binding on content.classifier, the code system used in the respective value set, the organization that defined the code system and the codes included in the respective value set.

Item	ValueSet	CodeSystem	Defined by	Codes
Certainty of Evidence	RatingCertaintyOfEvidence	EvidenceCertaintyRating	FHIR	high  moderate   low   very-low
Clinical Importance	RatingClinicalImportance	ClinicalImportance	CEOsys	1   2   3   4   5   6   7   8   9
Risk of Bias	RatingConcernDegree	EvidenceCertaintyRating	FHIR	no-concern   serious-concern   very-serious-concern   extremely-serious-concern
Inconsistency	RatingConcernDegree	EvidenceCertaintyRating	FHIR	no-concern   serious-concern   very-serious-concern   extremely-serious-concern
Indirectness	RatingConcernDegree	EvidenceCertaintyRating	FHIR	no-concern   serious-concern   very-serious-concern   extremely-serious-concern
Imprecision	RatingConcernDegree	EvidenceCertaintyRating	FHIR	no-concern   serious-concern   very-serious-concern   extremely-serious-concern
Publication Bias	RatingConcernDegree	EvidenceCertaintyRating	FHIR	no-concern   serious-concern   very-serious-concern   extremely-serious-concern
Large Effect	RatingUpratingTwoLevels	EvidenceCertaintyRating	FHIR	no-change   upcode1   upcode2
Plausible Confounders	RatingUpratingOneLevel	EvidenceCertaintyRating	FHIR	no-change   upcode1
Dose-Response Gradient	RatingUpratingOneLevel	EvidenceCertaintyRating	FHIR	no-change   upcode1

276 Table 3 Ratings in the CertaintyOfEvidenceRating profile. Shown are the ratings that are represented in the CertaintyOfEvidenceRating profile, together with the value set binding

277 on content.classifier, the code system used in the respective value set, the organization that defined the code system and the codes included in the respective value set.

#### 278 Outcome

The definition of an individual outcome (e.g., 30-day all-cause mortality), possibly including parameters
such as timing and method of outcome measurement, is represented using the *OutcomeDefinition*profile of *EvidenceVariable*.

The evidence for individual outcomes, i.e., summary statistics from systematic reviews of clinical studies or from primary studies, are represented by an instance of the *StudyOutcomeEvidence* profile (for primary studies) or *OutcomeEvidenceSynthesis* (for systematic reviews) of the *Evidence* resource. These instances hold the statistics associated with the particular outcome (e.g., the relative risk for intervention vs. comparison and the associated 95% confidence interval). For that purpose, *StudyOutcomeEvidence* and *OutcomeEvidenceSynthesis* may reference to the definition of an intervention and a comparison via the *InterventionDefinition* profile of *EvidenceVariable*.

As the study population may be different from the recommendation population, the StudyOutcomeEvidence and OutcomeEvidenceSynthesis profiles references the StudyEligibilityCriteria profile of EvidenceVariable for the intended definition of the population in the studies from which the evidence is derived. For the actually observed study population, the StudyCohort profile of Group is used for primary studies to describe the number of participants, and the EvidenceSynthesisCohorts profile of Group is used for systematic reviews, describing the total number studies and referencing the individual StudyCohort instances from the primary studies.

As the evidence on which a systematic review is based on is a dataset of results from primary studies, the *OutcomeEvidenceSynthesis* references the *EvidenceDataSet* profile of *EvidenceVariable*, which combines the *StudyOutcomeEvidence* instances from the primary studies into the dataset of the systematic review.

Additionally, *StudyOutcomeEvidence* and *OutcomeEvidenceSynthesis* may reference *StudyCitation* instances for the published systematic review and/or primary studies.

#### 302 Net Effect

The net effect is the overall expected effect of following a recommendation, calculated as an importance-weighted average of the individual outcome effects. It thus quantifies the balance between desirable and undesirable effects of an intervention [21]. When the net effect should be specified, it can be represented using the *NetEffectEstimate* profile of the *Evidence* resource. It references the individual outcomes that are included in the calculation of the net effect and their relative importance weightings as model characteristics.

#### 309 Guidelines

To represent the collection of multiple recommendations in a guideline, the *Guideline* profile of the *Composition* resource is used. The *Composition* resource sections are references to the individual *RecommendationPlan* instances that define the individual recommendations. Additionally, the guideline publication may be referenced via the *GuidelineCitation* profile of the *Citation* resource.

The whole collection of all resources defined here may be bundled using the *GuidelineBundle* profile of the *Bundle* resource.

#### 316 Terminologies

317 To identify the different contents of clinical practice guideline recommendations according to the PICO 318 framework, we used concepts from the Cochrane PICO ontology [15] as well as SNOMED CT concepts if available. To identify the rating types and values of the evidence-to-decision framework, we used 319 320 code systems defined by HL7 FHIR and developed new code systems if required (Table 2, Table 3). To 321 represent the clinical variables, the vocabularies intended to be used are the Systematized 322 Nomenclature of Medicine - Clinical Terms (SNOMED CT) for conditions, substances, and general 323 concepts [22], Logical Observation Identifiers Names and Codes (LOINC) for laboratory observation 324 [23], International Statistical Classification of Diseases and Related Health Problems, 10<sup>th</sup> revision (ICD-10) for diagnoses [24], Anatomical Therapeutic Chemical Classification System (ATC) for drugs [25] and 325 326 Unified Code for Units of Measure (UCUM) for measurement units [26]. Other vocabularies may be 327 used when suitable.


#### 328 Evaluation

329 To validate our proposed guideline recommendation structure, we implemented a recent 330 recommendation from a guideline for the treatment of COVID-19 intensive care patients [27–29]. As 331 this recommendation is part of a living guideline, it is ideally suited to validate the agility of our 332 proposed guideline recommendation representation as new evidence is added or certainty ratings for 333 specific outcomes or the actual recommendations changed. We selected a recommendation that 334 included both a treatment that should be performed on a specific population of patients and one that should not be performed on another population of patients. Specifically, the guideline includes a 335 336 recommendation for treating ventilated COVID-19 patients with the systemic corticosteroid 337 Dexamethasone, applied for 10 days orally or intravenously, and a recommendation against treating 338 non-ventilated patients with any Dexamethasone. The recommendation is based on a systematic 339 review [30], which is part of the evidence generation process. The different outcomes, most 340 importantly all-cause mortality, was evaluated as part of the evidence assessment process and the 341 recommendations were formulated based on the evaluated evidence (Figure 3). We created instances

342 for all appropriate profiles and included them as examples in the implementation guide [19] and on

### the FEvIR platform [31].

#### 344



345

346 Figure 3 Overview of the guideline recommendation implementation from a treatment guideline for

<sup>347</sup> hospitalized COVID-19 patients.

### 349 Discussion

350 We here present an EBMonFHIR-based representation for computer-interpretable guideline 351 recommendations that leverages the structured data emerging during the development of evidence-352 based guidelines, ranging from primary evidence-generating studies over systematic reviews and the 353 evidence assessment using evidence-to-decision frameworks to the formulated recommendation. We 354 have developed the representation based on an iterative, consensus-based requirements engineering 355 process and mapping of the thereby derived information model items to EBMonFHIR resources. We 356 developed profiles for all used FHIR resources and created an implementation guide for the guideline 357 representation format. To evaluate the format, we implemented a recent guideline recommendation 358 in our representation format.

The here presented computer-interpretable representation of the whole evidence-based guideline development process offers a set of advantages over just representing the final guideline recommendations:

First, representing the evidence from primary studies and systematic reviews (i.e., effect size statistics) and evidence-to-decision process artifacts in a computer-interpretable way allows them to be used for semi-automated guideline recommendation formulation. Indeed, knowledge artifacts from evidence generation and evidence assessment (i.e., ratings of existing evidence) in our representation format may be published in repositories, e.g. on collaborative guideline development platforms such as MAGICapp [32], and be reused for different guideline recommendation development processes.

Second, the representation of the evidence generation and evidence assessment artifacts may be
particularly valuable during the lifecycle of living guidelines that are regularly updated as new evidence
is published or existing evidence is re-evaluated in light of new findings.

371 Third, integrating a complete guideline recommendation representation into clinical decision support 372 or recommendation monitoring systems allows to close the loop from evidence to recommendation 373 back to evidence: Currently, the information flow is unidirectional from evidence generation via 374 evidence assessment to the formulated recommendation. However, when these recommendations 375 are implemented in a hospital setting by means of automated integration with electronic health 376 records (EHR), the treatment of patients according or not according to the recommendation in 377 connection with appropriate outcome data generates real-world evidence for (or against) the 378 intervention. This evidence, readily representable in the here proposed guideline recommendation 379 representation format, can be evaluated and used in an update process of the recommendation.

Fourth, representation of the full process of evidence-based recommendation development allows the
 target audience of the guideline recommendations a direct and transparent assessment of the

evidence generation and evidence assessment process that underlies the recommendations. It has to be noted that the structured evidence generation and evidence assessment artifacts are generated in any case within the context of a structured guideline recommendation development process; representing them in a computer-interpretable way therefore comes at no or only little further cost during guideline recommendation development.

387 Even though some of the existing guideline recommendation formalisms that only represent the final 388 guideline recommendations would allow to represent all of the information, the effort to newly encode 389 it from scratch appears as a relevant barrier. In contrast, the focus of our formalism is to enable using 390 data generated during the guideline recommendation development process, thus reducing the 391 required effort to include the additional data. However, as each representation formalism has its own 392 advantages and specialized scope of functions, our proposed representation might complement 393 existing formalisms instead of substituting them. In that way, mapping the treatment recommendation 394 part of our representation format to other formalisms would allow to close the gap between these 395 formalisms and the knowledge artifacts emerging during evidence-based guideline recommendation 396 development.

397 Apart from the previously described differences in content, in contrast to most previous guideline 398 recommendation formalisms, we have based our representation on FHIR, which currently might be 399 considered the most important standard for defining interoperable medical data exchange, with 400 growing support from EHR software vendors. There has been considerable work done on representing 401 the contents of clinical guideline recommendations in FHIR, namely the CPG-on-FHIR project [33]. This 402 project, like the EBMonFHIR project sponsored by the HL7 Clinical Decision Support Work Group, has 403 developed a comprehensive implementation guide for the representation of guideline 404 recommendation contents. However, in contrast to our project, the CPG-on-FHIR implementation 405 guide does not include profiles for linking the full evidence generation and evidence assessment 406 process to the final guideline recommendations - although for example the strength of 407 recommendation and quality of evidence are supported via FHIR extensions. Additionally, the CPG-on-408 FHIR project uses the Group resource for the definition of the population part of guideline 409 recommendations, whereas we are using the newly introduced characteristics backbone element of 410 the EvidenceVariable resource, which allows for much more complex definitions of patient group 411 characteristics than does the Group resource. To allow more complex definitions, the use of clinical 412 quality language (CQL) was introduced into the Group resource recently; additionally, it would be 413 possible to outsource the population characteristics definition into newly introduced concepts from a 414 code system. However, both solutions outsource the definition into another language or domain, 415 potentially reducing interoperability and limiting leveraging the query capabilities that are offered by 416 pure FHIR-based solutions. However, the CPG-on-FHIR project and our guideline recommendation

representation format are not mutually exclusive and combining efforts in the future may increase theutility of both approaches.

419 In the current work, we have not restricted the use of concepts in the definition of the population or 420 intervention to particular code systems such as SNOMED CT or LOINC. However, a major aim of our 421 representation, as of any computer-interpretable guideline recommendation formalism, is the 422 automated applicability in computerized clinical decision support systems. In such a setting, the 423 concepts used for the definition of the population and intervention must be mapped to the concepts 424 used in individual EHR systems in clinics. To reduce the need for additional mapping of concept and 425 variables, a possible approach is to provide the clinical data from the EHR system in the OMOP common 426 data model (CDM), as this uses a standardized vocabulary for clinical concepts, and further constraining 427 the profiles for the intervention (*RecommendationPlan, RecommendationAction*) and population ( 428 *RecommendationEligibilityCriteria*) to only allow concepts from the OMOP standardized vocabulary. 429 While this shifts the need of mapping individual EHR systems to concepts to the mapping to the OMOP 430 CDM, the provision of clinical data in OMOP CDM allows for a large range of clinical and research use case in the individual clinics, far beyond the integration of clinical guideline recommendations with the 431 432 clinical data. However, constraining FHIR resources to the use of OMOP standardized vocabulary 433 concepts is currently hampered by the unavailability of that vocabulary as a FHIR CodeSystem resource 434 and additional work is required to better link the two domains of FHIR and OMOP regarding OMOP's 435 standard vocabulary [34].

Our proposed FHIR-based representation of guideline recommendations has three main limitations: First, it is based on EBMonFHIR resources, which are mostly at a low maturity level and subject to frequent, even breaking, changes. The implementation guide therefore needs to be constantly kept in synchronization with current developments of EBMonFHIR resources. However, this is ensured by our active collaboration and participation in the development of the EBMonFHIR resources.

Second, there is currently no execution engine available for our representation format that would allow to automatically integrate the recommended interventions with clinical data to provide clinical decision support. However, a prototype implementation for such an execution engine to be used with clinical data in the OMOP common data model (CDM) format is currently being developed. Additionally, translators may be implemented that translate the FHIR-based representation to other guideline recommendation formalisms that already have an execution engine implemented (e.g. the GLIF3 execution engine or the SAGE execution engine for EON [35,36]).

Third, not all information for guideline recommendation execution can be expressed in current FHIR
 resources: The dependence and relationship between recommendations from the same or different
 guidelines cannot be modeled in the *PlanDefinition* resource without the introduction of extensions.

We expect that in the maturation process of resources from the Clinical Decision Support group, which maintains the *PlanDefinition* resource, and EBMonFHIR, additional concepts and relationships of declarative process modelling will be introduced to completely represent relationships between recommendations and guidelines.

The proposed EBMonFHIR-based guideline recommendation representation is currently being implemented in several German university hospitals, where it is used as a computer-interpretable guideline recommendation representation to be automatically integrated with standardized clinical patient data to provide information about individual patient guideline recommendation applicability and adherence. In the context of this project, and as the EBMonFHIR resources evolve, our guideline recommendation representation will be continuously updated and improved where necessary.

#### 461 Conclusion

462 To leverage the structured, computable knowledge artifacts that emerge during evidence-based 463 guideline recommendation development, we have developed a FHIR-based guideline 464 recommendation representation that is aligned with these knowledge artifacts. Thereby, our EBMonFHIR-based representation of clinical practice guideline recommendations allows to directly link 465 466 the systematic evidence assessment and the underlying evidence from systematic reviews and primary 467 studies to the resulting guideline recommendations. This not only allows for a transparent and critical 468 evaluation of the evidence on which recommendations are based, but also provides a more 469 straightforward and, in the future, automatable way to generate computer-interpretable guideline 470 recommendations from the available evidence.

## 472 Funding

The COVID-19 Evidence Ecosystem (CEOsys) project is funded under a scheme issued by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)) grant number 01KX2021. The CODEX+ project is funded under a scheme issued by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)) grant number 01KX2021. The CODEX+ project is funded under a scheme issued by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)) grant number 01KX2121.

## 480 Code availability

- 481 All code used for the development of the profiles and the implementation guide is available at
- 482 <u>https://github.com/CEOsys/cpg-on-ebm-on-fhir</u>. The implementation guide is hosted on
- 483 <u>https://ceosys.github.io/cpg-on-ebm-on-fhir/</u>. All code systems, value sets and examples are
- additionally hosted on the FEvIR platform [31].

## 486 References

487 [1] A. Seyfang, S. Miksch, M. Marcos, Combining diagnosis and treatment using asbru, Int. J. Med.
488 Inf. 68 (2002) 49–57. https://doi.org/10.1016/S1386-5056(02)00064-3.

489 [2] S.W. Tu, M.A. Musen, Modeling Data and Knowledge in the EON Guideline Architecture,
 490 MEDINFO 2001. (2001) 280–284. https://doi.org/10.3233/978-1-60750-928-8-280.

491 [3] A.A. Boxwala, M. Peleg, S. Tu, O. Ogunyemi, Q.T. Zeng, D. Wang, V.L. Patel, R.A. Greenes, E.H.
492 Shortliffe, GLIF3: a representation format for sharable computer-interpretable clinical practice
493 guidelines, J. Biomed. Inform. 37 (2004) 147–161. https://doi.org/10.1016/j.jbi.2004.04.002.

494 [4] S.W. Tu, J.R. Campbell, J. Glasgow, M.A. Nyman, R. McClure, J. McClay, C. Parker, K.M. Hrabak,
495 D. Berg, T. Weida, J.G. Mansfield, M.A. Musen, R.M. Abarbanel, The SAGE Guideline Model:
496 Achievements and Overview, J. Am. Med. Inform. Assoc. JAMIA. 14 (2007) 589–598.
497 https://doi.org/10.1197/jamia.M2399.

498 P. Ciccarese, E. Caffi, S. Quaglini, M. Stefanelli, Architectures and tools for innovative Health [5] 499 74 Information Systems: The Guide Project, Int. J. Med. Inf. (2005) 553-562. 500 https://doi.org/10.1016/j.ijmedinf.2005.02.001.

501 [6] M. Peleg, Computer-interpretable clinical guidelines: A methodological review, J. Biomed.
502 Inform. 46 (2013) 744–763. https://doi.org/10.1016/j.jbi.2013.06.009.

503 [7] D. Riaño, M. Peleg, A. ten Teije, Ten years of knowledge representation for health care (2009-504 2018): Artif. Intell. 100 (2019) Topics, trends, and challenges, Med. 101713. 505 https://doi.org/10.1016/j.artmed.2019.101713.

506 [8] B. Djulbegovic, G.H. Guyatt, Progress in evidence-based medicine: a quarter century on, The 507 Lancet. 390 (2017) 415–423. https://doi.org/10.1016/S0140-6736(16)31592-6.

508 [9] P. Alonso-Coello, H.J. Schünemann, J. Moberg, R. Brignardello-Petersen, E.A. Akl, M. Davoli, S. 509 Treweek, R.A. Mustafa, G. Rada, S. Rosenbaum, A. Morelli, G.H. Guyatt, A.D. Oxman, the G.W. Group, 510 GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well 511 informed healthcare choices. 1: Introduction, BMJ. 353 (2016) i2016. 512 https://doi.org/10.1136/bmj.i2016.

[10] P. Alonso-Coello, A.D. Oxman, J. Moberg, R. Brignardello-Petersen, E.A. Akl, M. Davoli, S.
Treweek, R.A. Mustafa, P.O. Vandvik, J. Meerpohl, G.H. Guyatt, H.J. Schünemann, the G.W. Group,
GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well

516 informed healthcare choices. 2: Clinical practice guidelines, BMJ. 353 (2016) i2089.
517 https://doi.org/10.1136/bmj.i2089.

[11] R. Graham, M. Mancher, D. Miller Wolman, S. Greenfield, E. Steinberg, eds., Clinical Practice
Guidelines We Can Trust, National Academies Press (US), Washington (DC), 2011.
https://doi.org/10.17226/13058.

[12] G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, J. Brozek, S. Norris, Y. Falck-Ytter, P. Glasziou,
H. deBeer, R. Jaeschke, D. Rind, J. Meerpohl, P. Dahm, H.J. Schünemann, GRADE guidelines: 1.
Introduction—GRADE evidence profiles and summary of findings tables, J. Clin. Epidemiol. 64 (2011)
383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026.

525 [13] B. Alper, M. Mayer, K. Shahin, J. Richardson, L. Schilling, M. Tristan, N. Salas, Achieving 526 evidence interoperability in the computer age: setting evidence on FHIR, BMJ Evid.-Based Med. 24 527 (2019) A15–A15. https://doi.org/10.1136/bmjebm-2019-EBMLive.28.

528 [14] What is CEOsys?, CEOsys. (n.d.). https://covid-evidenz.de/what-is-ceosys/ (accessed April 8, 529 2022).

530 [15] Cochrane PICO Ontology, (n.d.). https://data.cochrane.org/ontologies/pico/index-en.html 531 (accessed March 15, 2022).

532 [16] Clinical Practice Guidelines on EBMonFHIR, (2022). https://github.com/CEOsys/cpg-on-ebm-533 on-fhir (accessed March 15, 2022).

534 [17] G. Lichtner, FHIR Shorthand Validator, (2021). https://github.com/glichtner/fsh-validator 535 (accessed March 15, 2022).

536 [18] CEOsys, GitHub. (n.d.). https://github.com/CEOsys (accessed March 15, 2022).

537 [19] Clinical Practice Guidelines (CPG) on EBMonFHIR, (n.d.). https://ceosys.github.io/cpg-on-ebm-538 on-fhir/ (accessed March 15, 2022).

[20] C. Schardt, M.B. Adams, T. Owens, S. Keitz, P. Fontelo, Utilization of the PICO framework to
improve searching PubMed for clinical questions, BMC Med. Inform. Decis. Mak. 7 (2007) 16.
https://doi.org/10.1186/1472-6947-7-16.

542 [21] B.S. Alper, P. Oettgen, I. Kunnamo, A. Iorio, M.T. Ansari, M.H. Murad, J.J. Meerpohl, A. Qaseem,
543 M. Hultcrantz, H.J. Schünemann, G. Guyatt, Defining certainty of net benefit: a GRADE concept paper,
544 BMJ Open. 9 (2019) e027445. https://doi.org/10.1136/bmjopen-2018-027445.

545 [22] SNOMED CT, SNOMED. (n.d.). https://www.snomed.org/ (accessed March 16, 2022).

546 [23] C.J. McDonald, S.M. Huff, J.G. Suico, G. Hill, D. Leavelle, R. Aller, A. Forrey, K. Mercer, G.
547 DeMoor, J. Hook, W. Williams, J. Case, P. Maloney, for the Laboratory LOINC Developers, LOINC, a
548 Universal Standard for Identifying Laboratory Observations: A 5-Year Update, Clin. Chem. 49 (2003)
549 624–633. https://doi.org/10.1373/49.4.624.

550[24]InternationalClassificationofDiseases(ICD),(n.d.).551https://www.who.int/standards/classifications/classification-of-diseases (accessed March 22, 2022).

552 [25] Anatomical Therapeutic Chemical (ATC) Classification, (n.d.). https://www.who.int/tools/atc-553 ddd-toolkit/atc-classification (accessed March 22, 2022).

554 [26] The Unified Code for Units of Measure, (n.d.). https://ucum.org/trac (accessed March 16, 2022).

556 [27] S. Kluge, U. Janssens, T. Welte, S. Weber-Carstens, G. Schälte, Christoph D. Spinner, Jakob J.
557 Malin, Petra Gastmeier, Florian Langer, Martin Wepler, Michael Westhoff, Michael Pfeifer, Klaus F.
558 Rabe, Florian Hoffmann, Bernd W. Böttiger, Julia Weinmann-Menke, Alexander Kersten, Peter Berlit,
559 Marcin Krawczyk, Wiebke Nehls, Reiner Haase, Monika Nothacker, Gernot Marx, Christian
560 Karagiannidis, S3-Leitlinie Empfehlungen zur stationären Therapie von Patienten mit COVID-19, AWMF
561 (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.), 2021.
562 https://www.awmf.org/leitlinien/detail/ll/113-001LG.html.


563 [28] S. Kluge, U. Janssens, C.D. Spinner, M. Pfeifer, G. Marx, C. Karagiannidis, Guideline group,
564 Clinical Practice Guideline: Recommendations on Inpatient Treatment of Patients with COVID-19,
565 Dtsch. Arzteblatt Int. 118 (2021) arztebl.m2021.0110. https://doi.org/10.3238/arztebl.m2021.0110.

J.J. Malin, C.D. Spinner, U. Janssens, T. Welte, S. Weber-Carstens, G. Schälte, P. Gastmeier, F.
Langer, M. Wepler, M. Westhoff, M. Pfeifer, K.F. Rabe, F. Hoffmann, B.W. Böttiger, J. WeinmannMenke, A. Kersten, P. Berlit, M. Krawczyk, W. Nehls, F. Fichtner, S. Laudi, M. Stegemann, N. Skoetz, M.
Nothacker, G. Marx, C. Karagiannidis, S. Kluge, Key summary of German national treatment guidance
for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German
living guideline using an Evidence to Decision Framework (last updated 17.05.2021), Infection. (2021).
https://doi.org/10.1007/s15010-021-01645-2.

573 C. Wagner, M. Griesel, A. Mikolajewska, A. Mueller, M. Nothacker, K. Kley, M.-I. Metzendorf, [30] 574 A.-L. Fischer, M. Kopp, M. Stegemann, N. Skoetz, F. Fichtner, Systemic corticosteroids for the treatment 575 of COVID-19, Cochrane Database Syst. Rev. 8 (2021)CD014963. 576 https://doi.org/10.1002/14651858.CD014963.

- 577 [31] FEVIR Project CPG-on-EBMonFHIR, FEVIR Platf. (n.d.).
  578 https://fevir.net/resources/Project/46952 (accessed May 13, 2022).
- 579 [32] MAGICapp, (n.d.). https://app.magicapp.org/ (accessed March 21, 2022).
- 580 [33] FHIR Clinical Guidelines (v1.0.0) (STU 1), (n.d.). http://hl7.org/fhir/uv/cpg/index.html 581 (accessed March 15, 2022).
- 582 [34] M. Lawley, J. Steel, J. Grimes, FHIR Terminology Services for OMOP opportunities report, 583 (n.d.) 21.
- 584 [35] D. Wang, M. Peleg, S.W. Tu, A.A. Boxwala, O. Ogunyemi, Q. Zeng, R.A. Greenes, V.L. Patel, E.H.
- Shortliffe, Design and implementation of the GLIF3 guideline execution engine, J. Biomed. Inform. 37
  (2004) 305–318. https://doi.org/10.1016/j.jbi.2004.06.002.
- 587 [36] D. Isern, A. Moreno, Computer-based execution of clinical guidelines: A review, Int. J. Med. Inf.
- 588 77 (2008) 787–808. https://doi.org/10.1016/j.ijmedinf.2008.05.010.

## 590 Supplementary Figures



592 Supplementary Figure 1 Class Diagram of CPG-on-EBMonFHIR profiles.